Report from the Extraordinary General Meeting of Vitrolife AB (publ) held on September 24, 2012
- The meeting adopted a resolution to distribute shares in the subsidiary Xvivo Perfusion AB to company shareholders, whereby one (1) existing share in Vitrolife AB entitles shareholders to distribution of one (1) share in Xvivo Perfusion AB. After the shareholders’ contribution of SEK 65,400,000 from Vitrolife AB, Xvivo Perfusion AB has a book value of SEK 65,518,757, which corresponds to a figure of approximately SEK 3.35 per share. After the shareholders’ contribution has been completed, SEK 113,799,910 remains of the unappropriated amount in accordance with chap.17 § 3, paragraph one of the Swedish Companies Act. The last day for trade in Vitrolife shares with entitlement to the distribution of shares in Xvivo is September 26 The record day is October 1.The record day is October 1, 2012.
- The meeting adopted a resolution regarding a private placement of EUR 1,352,315 in order to partly finance acquisition of Cryo Management Ltd. The Company Board, or the person on the Board appointed by the Board, is authorized, before the start of the subscription period, to make a decision regarding the highest amount that the Company’s share capital may be increased by, the highest number of shares that may be issued and what amount is to be paid for each new share. The new shares are to be issued at a subscription price per share corresponding to the average closing price for the Company’s shares during the fifteen trading days immediately subsequent to the Company’s shares being traded exclusive of entitlement to distribution of shares in the Company’s subsidiary Xvivo Perfusion AB, based on an average EUR/SEK exchange rate during the aforesaid fifteen trading days.
Shares shall be subscribed for through subscription on the subscription list no earlier than October 25, 2012 and no later than October 26, 2012. The Board shall be entitled to extend the subscription period. Those entitled to subscribe are former shareholders of Cryo Management Ltd.
The new shares entitle shareholders to dividend for the first time on the record day for dividend that falls immediately after the new share issue has been registered at the Swedish Companies Registration Office and the shares have been entered in the share register at Euroclear Sweden AB.
Queries should be addressed to:
Patrik Tigerschiöld, Chairman of the Board, phone 46 8 614 00 20
Mikael Engblom, CFO, phone 46 31 721 80 14
Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on September 24, at 4.35 p.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
Vitrolife is a global biotechnology/medical device Group that works in the areas of Fertility and Transplantation. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes. The Transplantation product area works with solutions and systems for assessing and preserving organs outside the body, so as to be able to select usable organs and keep them in optimal condition pending transplantation.
Vitrolife today has approximately 220 employees and its products are sold in almost 90 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China and Japan. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.
_________________________________________________________________________________________________________________
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/
Tags: